In this study, we delineated the mutational profiles of 380 baseline and 71 EGFR-mutated NSCLC patients who acquired RET fusions after resistance to EGFR-TKIs by targeted NGS and revealed RET fusion partners associated with primary and acquired patients. Here, RET is linked to non-small cell lung carcinoma.